These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26831742)

  • 41. [Direct-to-consumer genetic testing: a regulation by the market, or a medical regulation?].
    Jautrou H
    Med Sci (Paris); 2020 Feb; 36(2):153-159. PubMed ID: 32129752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Harmonisation of regulatory requirements for clinical trials on medicinal products for human use in the Directive 2001/20/EC and complementary guidance. Implementation of the 12th Law Amending the German Drug Law].
    Geisler I; Hofmann HP; Nickel L
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):141-6. PubMed ID: 15726454
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Health policy in the European Union: impact on the Spanish health system].
    Guimarães L; Freire JM
    Cad Saude Publica; 2007; 23 Suppl 2():S143-54. PubMed ID: 17625642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The European Union, economies and public health: not one without the other.
    Vervoort D; van Daalen KR
    Public Health; 2021 May; 194():1-3. PubMed ID: 33836317
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Challenges to sovereign ambitions: forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European Union.
    Wright JSF; Doukas D
    Health Econ Policy Law; 2021 Jul; 16(3):256-272. PubMed ID: 32583755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Impact Reimbursement Act on the pharmaceutical market in Poland].
    Giermaziak W
    Pol Merkur Lekarski; 2014 Apr; 36(214):270-3. PubMed ID: 24868902
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use: an overview.
    Petrini C
    Ann Ist Super Sanita; 2014; 50(4):317-21. PubMed ID: 25522070
    [TBL] [Abstract][Full Text] [Related]  

  • 48. European Health Care Systems and the Emerging Influence of European Union Competition Policy.
    Morton AJB
    J Health Polit Policy Law; 2021 Jun; 46(3):467-486. PubMed ID: 33647978
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical Trials Legislation - preparing for the revision of the European Directive Scheduled for 2011.
    Bilbault P; Belorgey C; Zannad F; Golinelli D; Pletan Y;
    Therapie; 2010; 65(4):301-8, 291-9. PubMed ID: 20854751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is the increasing policy use of Impact Assessment in Europe likely to undermine efforts to achieve healthy public policy?
    Smith KE; Fooks G; Collin J; Weishaar H; Gilmore AB
    J Epidemiol Community Health; 2010 Jun; 64(6):478-87. PubMed ID: 20466716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)].
    Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Application challenges of the new EU Clinical Trials Regulation.
    Gefenas E; Cekanauskaite A; Lekstutiene J; Lukaseviciene V
    Eur J Clin Pharmacol; 2017 Jul; 73(7):795-798. PubMed ID: 28567502
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breast cancer research and the European Union Clinical Trials Directive.
    Williams N
    Breast Cancer Res; 2004; 6(4):145-7. PubMed ID: 15217484
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Juridification, medicalisation, and the impact of EU Law: patient mobility and the allocation of scarce NHS resources.
    Veitch K
    Med Law Rev; 2012; 20(3):362-98. PubMed ID: 22535326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical trials in Germany and in the EU in the new legislative environment. An analysis from the industry's point of view].
    Heidenreich K; Möritz A; Löffler H; Oberle-Rolle B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):415-22. PubMed ID: 15830252
    [TBL] [Abstract][Full Text] [Related]  

  • 56. European policies for public health in border regions: no European mindset as yet.
    van der Zanden BAM; Hoebe CJPA; Horstman K
    BMC Public Health; 2024 Mar; 24(1):746. PubMed ID: 38459505
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Policy Effect of the General Data Protection Regulation (GDPR) on the Digital Public Health Sector in the European Union: An Empirical Investigation.
    Yuan B; Li J
    Int J Environ Res Public Health; 2019 Mar; 16(6):. PubMed ID: 30934648
    [TBL] [Abstract][Full Text] [Related]  

  • 59. StatBite: Key findings from the "Impact on clinical research of European legislation" report.
    J Natl Cancer Inst; 2010 Mar; 102(5):293. PubMed ID: 20173122
    [No Abstract]   [Full Text] [Related]  

  • 60. Nanotechnology in global medicine and human biosecurity: private interests, policy dilemmas, and the calibration of public health law.
    Faunce TA
    J Law Med Ethics; 2007; 35(4):629-42, 512. PubMed ID: 18076514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.